請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70663
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賴逸儒(I-Rue Lai) | |
dc.contributor.author | Yi-En Li | en |
dc.contributor.author | 李怡恩 | zh_TW |
dc.date.accessioned | 2021-06-17T04:34:10Z | - |
dc.date.available | 2020-09-06 | |
dc.date.copyright | 2018-09-06 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-09 | |
dc.identifier.citation | 1. Dunn, G.P., L.J. Old, and R.D. Schreiber, The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 2004. 21(2): p. 137-48.
2. Braumuller, H., et al., T-helper-1-cell cytokines drive cancer into senescence. Nature, 2013. 494(7437): p. 361-5. 3. Shiao, S.L., et al., Immune microenvironments in solid tumors: new targets for therapy. Genes Dev, 2011. 25(24): p. 2559-72. 4. Hodi, F.S., et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010. 363(8): p. 711-23. 5. O'Day, S.J., O. Hamid, and W.J. Urba, Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer, 2007. 110(12): p. 2614-27. 6. Fong, L. and E.J. Small, Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol, 2008. 26(32): p. 5275-83. 7. Maude, S.L., et al., CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 2015. 125(26): p. 4017-23. 8. Fraietta, J.A., et al., Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 2018. 558(7709): p. 307-312. 9. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 144(5): p. 646-74. 10. Mellman, I., G. Coukos, and G. Dranoff, Cancer immunotherapy comes of age. Nature, 2011. 480(7378): p. 480-9. 11. Chen, W. and J.E. Konkel, TGF-beta and 'adaptive' Foxp3(+) regulatory T cells. J Mol Cell Biol, 2010. 2(1): p. 30-6. 12. Oh, S.A. and M.O. Li, TGF-beta: guardian of T cell function. J Immunol, 2013. 191(8): p. 3973-9. 13. Gorelik, L. and R.A. Flavell, Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med, 2001. 7(10): p. 1118-22. 14. Sa, G., et al., GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res, 2009. 69(7): p. 3095-104. 15. Wondimu, A., et al., Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells. Cancer Res, 2014. 74(19): p. 5449-57. 16. Kim, J., et al., IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol, 1995. 155(4): p. 2240-7. 17. Sevko, A. and V. Umansky, Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer, 2013. 4(1): p. 3-11. 18. Sato, T., et al., Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res, 2011. 51(2-3): p. 170-82. 19. Wu, A.A., et al., Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology, 2015. 4(7): p. e1016700. 20. Whiteside, T.L., The role of regulatory T cells in cancer immunology. Immunotargets Ther, 2015. 4: p. 159-71. 21. Tanchot, C., et al., Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron, 2013. 6(2): p. 147-57. 22. Shevach, E.M., Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity, 2009. 30(5): p. 636-45. 23. Sitkovsky, M.V., et al., Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res, 2008. 14(19): p. 5947-52. 24. Quezada, S.A., et al., CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest, 2006. 116(7): p. 1935-45. 25. Peterson, R.A., Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol, 2012. 40(2): p. 186-204. 26. Campbell, D.J. and M.A. Koch, Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol, 2011. 11(2): p. 119-30. 27. Czystowska, M., et al., Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med (Berl), 2010. 88(6): p. 577-88. 28. Strauss, L., C. Bergmann, and T.L. Whiteside, Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol, 2009. 182(3): p. 1469-80. 29. Chen, M.L., et al., Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A, 2005. 102(2): p. 419-24. 30. Peng, Y., et al., TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A, 2004. 101(13): p. 4572-7. 31. Chen, W., et al., Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 2003. 198(12): p. 1875-86. 32. Fantini, M.C., et al., Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol, 2004. 172(9): p. 5149-53. 33. Strauss, L., et al., A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res, 2007. 13(15 Pt 1): p. 4345-54. 34. Strauss, L., et al., The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res, 2007. 13(21): p. 6301-11. 35. Mougiakakos, D., et al., Regulatory T cells in cancer. Adv Cancer Res, 2010. 107: p. 57-117. 36. Nishikawa, H. and S. Sakaguchi, Regulatory T cells in tumor immunity. Int J Cancer, 2010. 127(4): p. 759-67. 37. Bergmann, C., et al., T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res, 2008. 14(12): p. 3706-15. 38. Yamamoto, T., et al., Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas, 2012. 41(3): p. 409-15. 39. Curiel, T.J., et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004. 10(9): p. 942-9. 40. Bates, G.J., et al., Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol, 2006. 24(34): p. 5373-80. 41. Perrone, G., et al., Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer, 2008. 44(13): p. 1875-82. 42. Shang, B., et al., Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep, 2015. 5: p. 15179. 43. Takahashi, T., et al., Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol, 1998. 10(12): p. 1969-80. 44. Read, S., V. Malmstrom, and F. Powrie, Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med, 2000. 192(2): p. 295-302. 45. Whiteside, T.L., What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol, 2012. 22(4): p. 327-34. 46. Bashyam, H., CTLA-4: From conflict to clinic. J Exp Med, 2007. 204(6): p. 1243. 47. Lipson, E.J. and C.G. Drake, Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res, 2011. 17(22): p. 6958-62. 48. Guazzelli, A., et al., Anti-CTLA-4 therapy for malignant mesothelioma. Immunotherapy, 2017. 9(3): p. 273-280. 49. Bertrand, A., et al., Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med, 2015. 13: p. 211. 50. Gouirand, V., F. Guillaumond, and S. Vasseur, Influence of the Tumor Microenvironment on Cancer Cells Metabolic Reprogramming. Front Oncol, 2018. 8: p. 117. 51. Warburg, O., On the origin of cancer cells. Science, 1956. 123(3191): p. 309-14. 52. Chang, C.H., et al., Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell, 2013. 153(6): p. 1239-51. 53. Ho, P.C., et al., Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell, 2015. 162(6): p. 1217-28. 54. Chang, C.H., et al., Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell, 2015. 162(6): p. 1229-41. 55. Zhao, E., et al., Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol, 2016. 17(1): p. 95-103. 56. Reina-Campos, M., J. Moscat, and M. Diaz-Meco, Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol, 2017. 48: p. 47-53. 57. Lyssiotis, C.A. and A.C. Kimmelman, Metabolic Interactions in the Tumor Microenvironment. Trends Cell Biol, 2017. 27(11): p. 863-875. 58. Molon, B., B. Cali, and A. Viola, T Cells and Cancer: How Metabolism Shapes Immunity. Front Immunol, 2016. 7: p. 20. 59. Macintyre, A.N., et al., The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab, 2014. 20(1): p. 61-72. 60. MacIver, N.J., R.D. Michalek, and J.C. Rathmell, Metabolic regulation of T lymphocytes. Annu Rev Immunol, 2013. 31: p. 259-83. 61. Sukumar, M., et al., Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest, 2013. 123(10): p. 4479-88. 62. Michalek, R.D., et al., Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol, 2011. 186(6): p. 3299-303. 63. Shi, L.Z., et al., HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med, 2011. 208(7): p. 1367-76. 64. Pearce, E.L., et al., Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature, 2009. 460(7251): p. 103-7. 65. Buck, M.D., et al., Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. Cell, 2016. 166(1): p. 63-76. 66. O'Neill, L.A., R.J. Kishton, and J. Rathmell, A guide to immunometabolism for immunologists. Nat Rev Immunol, 2016. 16(9): p. 553-65. 67. Procaccini, C., et al., An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity, 2010. 33(6): p. 929-41. 68. Pearce, E.L. and E.J. Pearce, Metabolic pathways in immune cell activation and quiescence. Immunity, 2013. 38(4): p. 633-43. 69. Sun, L., J. Fu, and Y. Zhou, Metabolism Controls the Balance of Th17/T-Regulatory Cells. Front Immunol, 2017. 8: p. 1632. 70. Berod, L., et al., De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med, 2014. 20(11): p. 1327-33. 71. Gerriets, V.A., et al., Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest, 2015. 125(1): p. 194-207. 72. Torre, L.A., et al., Global cancer statistics, 2012. CA Cancer J Clin, 2015. 65(2): p. 87-108. 73. Van Cutsem, E., et al., Gastric cancer. Lancet, 2016. 388(10060): p. 2654-2664. 74. Stock, M. and F. Otto, Gene deregulation in gastric cancer. Gene, 2005. 360(1): p. 1-19. 75. Parkin, D.M., et al., Global cancer statistics, 2002. CA Cancer J Clin, 2005. 55(2): p. 74-108. 76. Abe, N., et al., Risk factors predictive of lymph node metastasis in depressed early gastric cancer. Am J Surg, 2002. 183(2): p. 168-72. 77. Chen, C.Y., et al., Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology, 2002. 49(45): p. 874-7. 78. Hoshino, A., et al., Tumour exosome integrins determine organotropic metastasis. Nature, 2015. 527(7578): p. 329-35. 79. Wieckowski, E.U., et al., Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol, 2009. 183(6): p. 3720-30. 80. Wang, F., et al., Tumor-derived exosomes induce PD1(+) macrophage population in human gastric cancer that promotes disease progression. Oncogenesis, 2018. 7(5): p. 41. 81. Chen, K.B., et al., Exosome-mediated peritoneal dissemination in gastric cancer and its clinical applications. Biomed Rep, 2018. 8(6): p. 503-509. 82. Ning, X., et al., Exosomes Released by Gastric Cancer Cells Induce Transition of Pericytes Into Cancer-Associated Fibroblasts. Med Sci Monit, 2018. 24: p. 2350-2359. 83. Zhao, H., et al., Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife, 2016. 5: p. e10250. 84. Thery, C., et al., Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol, 2006. Chapter 3: p. Unit 3 22. 85. Muller, L., et al., Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms. Oncoimmunology, 2017. 6(8): p. e1261243. 86. Rao, Q., et al., Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro. Hepatology, 2016. 64(2): p. 456-72. 87. Yen, E.Y., et al., Exosomal TGF-beta1 is correlated with lymphatic metastasis of gastric cancers. Am J Cancer Res, 2017. 7(11): p. 2199-2208. 88. Szajnik, M., et al., Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One, 2010. 5(7): p. e11469. 89. Wada, J., et al., Surface-bound TGF-beta1 on effusion-derived exosomes participates in maintenance of number and suppressive function of regulatory T-cells in malignant effusions. Anticancer Res, 2010. 30(9): p. 3747-57. 90. De Rosa, V., et al., Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat Immunol, 2015. 16(11): p. 1174-84. 91. Shrestha, S., et al., Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat Immunol, 2015. 16(2): p. 178-87. 92. Huynh, A., et al., Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat Immunol, 2015. 16(2): p. 188-96. 93. Siska, P.J., et al., Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. J Immunol, 2016. 197(6): p. 2532-40. 94. Gerriets, V.A. and J.C. Rathmell, Metabolic pathways in T cell fate and function. Trends Immunol, 2012. 33(4): p. 168-73. 95. Roberts, D.J. and S. Miyamoto, Hexokinase II integrates energy metabolism and cellular protection: Akting on mitochondria and TORCing to autophagy. Cell Death Differ, 2015. 22(2): p. 248-57. 96. Miyamoto, S., A.N. Murphy, and J.H. Brown, Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ, 2008. 15(3): p. 521-9. 97. John, S., J.N. Weiss, and B. Ribalet, Subcellular localization of hexokinases I and II directs the metabolic fate of glucose. PLoS One, 2011. 6(3): p. e17674. 98. Ray, J.P., et al., The Interleukin-2-mTORc1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells. Immunity, 2015. 43(4): p. 690-702. 99. Brennan, P., et al., Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity, 1997. 7(5): p. 679-89. 100. Sinclair, L.V., et al., Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol, 2013. 14(5): p. 500-8. 101. Burchill, M.A., et al., IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol, 2007. 178(1): p. 280-90. 102. Nelson, B.H., IL-2, regulatory T cells, and tolerance. J Immunol, 2004. 172(7): p. 3983-8. 103. Moon, B.I., T.H. Kim, and J.Y. Seoh, Functional Modulation of Regulatory T Cells by IL-2. PLoS One, 2015. 10(11): p. e0141864. 104. Jeffery, H.C., et al., Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol, 2017. 188(3): p. 394-411. 105. Jenei, Z.A., et al., Self-association of transmembrane domain 2 (TM2), but not TM1, in carnitine palmitoyltransferase 1A: role of GXXXG(A) motifs. J Biol Chem, 2009. 284(11): p. 6988-97. 106. Lee, K., J. Kerner, and C.L. Hoppel, Mitochondrial carnitine palmitoyltransferase 1a (CPT1a) is part of an outer membrane fatty acid transfer complex. J Biol Chem, 2011. 286(29): p. 25655-62. 107. Thomou, T., et al., Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature, 2017. 542(7642): p. 450-455. 108. Skog, J., et al., Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol, 2008. 10(12): p. 1470-6. 109. van der Vos, K.E., et al., Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro Oncol, 2016. 18(1): p. 58-69. 110. Thery, C., et al., Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol, 2001. 166(12): p. 7309-18. 111. Clayton, A., et al., Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods, 2001. 247(1-2): p. 163-74. 112. van Balkom, B.W., et al., Quantitative and qualitative analysis of small RNAs in human endothelial cells and exosomes provides insights into localized RNA processing, degradation and sorting. J Extracell Vesicles, 2015. 4: p. 26760. 113. Li, M., et al., Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers. Philos Trans R Soc Lond B Biol Sci, 2014. 369(1652). 114. Yagi, Y., et al., Next-generation sequencing-based small RNA profiling of cerebrospinal fluid exosomes. Neurosci Lett, 2017. 636: p. 48-57. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70663 | - |
dc.description.abstract | 在有氧氣環境中,癌細胞仍偏好使用糖解作用來產生能量。當葡萄糖因癌細胞使用糖解作用而消耗時,微環境中的的免疫淋巴球的葡萄糖來源即受到影響,進而影響到免疫細胞抗癌的功能。目前許多研究指出,細胞代謝路徑的改變,例如糖解作用、有氧磷酸化、脂肪酸代謝等皆會影響輔助型T細胞 (T helper cells) 的分化並影響他們的免疫功能。在癌症的研究上,發現癌細胞所分泌的外質體會先至其預轉移的部位進行微環境的調節,使癌細胞在後續轉移的過程中更順利。在之前的研究中,我們已經證實癌細胞所分泌的外質體可以促進調節型T細胞 (regulatory T cells) 的產生,而調節型T細胞正是使癌細胞逃離免疫系統監控的關鍵。
本研究中,我們假設,胃癌分泌的外質體可能會透過調節naïve T細胞的代謝途徑使其分化成FOXP3+調節型T細胞。我們首先將胃癌病人血液中的外質體分離出來,並透過檢測細胞的糖解能力狀況,探討胃癌所分泌的外質體對於T 細胞在分化過程中的代謝影響。細胞代謝的狀況由螢光偵測,同時也透過西方墨點法觀察T細胞中跟代謝相關的酵素與蛋白的表現,包括己糖激酶(Hexokinase II), 肉鹼棕櫚醯基轉移酶 (CPT1A) 以及葡萄糖載體蛋白 (GLUT1)。 實驗結果發現,無論是由乙型轉化生長因子(rhTGF-β)或胃癌病患血液分離出來之外質體所誘導的調節性T細胞,均有較高的糖解速率。在西方墨點法的實驗中,由乙型轉化生長因子所誘導的調節性T細胞,其己糖激酶,肉鹼棕櫚醯基轉移酶以及葡萄糖載體蛋白都明顯高於未分化的naïve T細胞。而由胃癌病患血液分離出來之外質體體誘導的調節性T細胞組別中,其己糖激酶與肉鹼棕櫚醯基轉移酶的表現均高於乙型轉化生長因子所誘導的調節性T細胞。 吾人的結果顯示,癌細胞外質體不僅與乙型轉化生長因子有相同的作用能將T細胞誘導成為調節性T細胞,同時也提升其糖解代謝能力,甚至在糖激酶與肉鹼棕櫚醯基轉移酶的表現均高於乙型轉化生長因子所誘導的調節性T細胞。因此,癌細胞所分泌的外質體中,或許含有能夠影響調節性T細胞代謝能力的因子。 | zh_TW |
dc.description.abstract | Cancer cells regularly use glycolysis despite the presence of oxygen, which promotes the depletion of extracellular glucose in tumor microenvironment and causes tumor infiltrating T cells (TILs) dysfunction. Recently, many studies indicated the modulations of major intracellular metabolic pathways, such as glycolysis, oxidative phosphorylation and fatty acid oxidation in T cells could influence the differentiation of the T helper subtype and shaped their function. In our previously study, we have showed tumor-derived exosomes could promote regulatory T cells expansion, facilitate tumor cells to escape from immune surveillance.
In this study, we hypothesis that tumor-derived exosomes promote naïve T cells to differentiate into FOXP3+ regulatory T cells by reprogramming the metabolism pathway. The tumor-derived exosomes were isolated from the peripheral blood of gastric cancer (GC) patients. The metabolic phenotypes of glycolysis of T cells with or without GC-derived exosomes treatment were detected by the time-resolved fluorescence probes. The expression of metabolic enzymes, including Hexokinase II, CPT1A and GLUT1 in Treg cells and GC-derived exosomes-induced Treg cells were analyzed by Western blot. In our results, the expression of both rhTGF-β and GC-derived exosomes treated T cells have higher glycolysis rate and Hexokinase II, CPT1A expression than naïve T cells. Compared to rhTGF-β induced regulatory T cells, GC-derived exosomes induced more expression of HK2 and CPT1A in regulatory T cells. Therefore, GC-derived exosomes may regulate cellular metabolism to affect the differentiation of FOXP3+regulatory T cells. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T04:34:10Z (GMT). No. of bitstreams: 1 ntu-107-R05446001-1.pdf: 2812775 bytes, checksum: 748d1967987330cb988245908a5097b8 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員審定書 i
致謝 ii 摘要 iii Abstract v Contents vii I. Introduction - 1 - 1-1 The tumor-induced immune suppression in tumor microenvironment - 2 - 1-2 Phenotypic and functional characteristics of human regulatory T cells - 3 - 1-3 Metabolic competition in the tumor microenvironment - 4 - 1-4 Reprogramming immunometabolism of regulatory T cells - 5 - 1-5 Tumor-derived exosomes and gastric cancer - 6 - 1-6 Aim in the study - 8 - II. Material and Methods - 9 - 2-1 Human samples collection - 9 - 2-2 Primary T cells isolation, culture and differentiation - 9 - 2-3 Exosomes purification, characterization and analysis - 10 - 2-4 Nanoparticle tracking analysis - 11 - 2-5 Flow cytometry analysis - 11 - 2-6 Metabolic phenotyping - 12 - 2-7 Western blot analysis - 13 - 2-8 Statistics - 14 - III. Result - 15 - 3-1 Characteristics of purified exosomes from gastric cancer patients - 15 - 3-2 Induction of Tregs from naïve T cells by exosomes from GC patients - 15 - 3-3 The metabolic phenotyping of glycolysis in GC-derived exosomes-induced Treg cells - 16 - 3-4 The expression of metabolic enzymes in GC-derived exosome-induced Treg cells - 17 - IV. Discussion - 18 - Conclusion - 23 - V. Figures - 24 - Figure 1. Verification of purified exosomes from peripheral blood of gastric cancer patients utilizing NTA and Western blot. - 24 - Figure 2. The induction of human iTreg cells from GC-derived exosomes. - 26 - Figure 3. GC-derived exosomes increase the glycolysis in human iTreg cells. - 27 - Figure 4. The expression of metabolic enzymes in Treg cells with GC-derived exosomes treatment. - 29 - VI. References - 31 - | |
dc.language.iso | en | |
dc.title | 腫瘤外質體對調節型T 細胞的代謝與分化上之影響 | zh_TW |
dc.title | The effect of tumor-derived exosomes on
metabolism and differentiation of the regulatory T cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 繆希椿(Shi?Chuen Miaw),陳玉怜(Yuh-Lien Chen) | |
dc.subject.keyword | 胃癌,外質體,代謝,調節型T細胞,腫瘤微環境,糖解作用, | zh_TW |
dc.subject.keyword | gastric cancer (GC),exosome,metabolism,FOXP3+regulatory T (Treg) cell,tumor microenvironment,glycolysis, | en |
dc.relation.page | 39 | |
dc.identifier.doi | 10.6342/NTU201802843 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-10 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 解剖學暨細胞生物學研究所 | zh_TW |
顯示於系所單位: | 解剖學暨細胞生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 2.75 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。